Hypertension and stroke: 2005 Canadian Hypertension Educational Program recommendations

Canadian Journal of Neurological Sciences

Volumn 32, Issue 4, 2005, Pages 403-408

  Boulanger, Jean Martin ^a   Hill, Michael D ^a  

^a FOOTHILLS HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CONTRACEPTIVE AGENT; CORTICOSTEROID; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPHEDRINE; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PSEUDOEPHEDRINE; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE REGULATION; CANADA; CLINICAL TRIAL; DIABETES MELLITUS; DRUG CONTRAINDICATION; EVIDENCE BASED MEDICINE; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; HYPERTENSION; HYPOKALEMIA; KIDNEY DISEASE; LIFESTYLE; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SEX DIFFERENCE; STROKE; SYSTEMATIC REVIEW; WAIST CIRCUMFERENCE;

EID: 29044444723     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100004376     Document Type: Review

References (34)

1. American Heart Association statistics. Available at: www.americanheart. org.
2. Mohr JP, Choi DW, Grotta JC, et al. Stroke: Pathophysiology, diagnosis, and management. Churchill Livingstone 2004. 4th ed. page 15.
3. Langille DB, Joffres MR, MacPherson KM, et al. Prevalence of risk factors for cardiovascular disease in Canadians 55 to 74 years of age: results from the Canadian Heart Health Surveys, 1986-1992. CMAJ 1999;161(8 Suppl):S3-9.
4. Yiannakoulias N, Svenson LW, Hill MD, et al. Incident cerebrovascular disease in rural and urban Alberta. Cerebrovasc Dis 2004;17:72-78.
5. Bobrie G, Chatellier G, Genes N et al. Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004;291:1342-1349.
6. Asayama K, Ohkubo T, Kikuya M, et al. Prediction of stroke by self-measurement of blood pressure at home versus casual screening blood pressure measurement in relation to the Joint National Committee 7 Classification. The Ohsama study. Stroke 2004;35:2356-2361.
7. Ohkubo T, Imai Y, Tsuji I, et al. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens 1998;16:971-975.
8. Clement DL, De Buyzere ML, De Bacquer Da, et al. For the Office versus Ambulatory (OvA) Pressure Study Investigators. Prognostic value of ambulatory blood pressure recordings in patients with treated hypertension. N Engl J Med 2003;348:2407-2415.
9. Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999;282:539-546.
10. Thijs L, Staessen JA, Celis H, et al. Reference values for self-recorded blood pressure: a meta-analysis of summary data. Arch Intern Med 1998;158:481-488.
11. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031.
12. Poole-Wilson PA, Lubsen J, Kirwan BA, et al for the A Coronary Disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system (ACTION trial) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): A randomised controlled trial. Lancet 2004;364:849-857.
13. Pepine CJ, Handberg EM, Cooper-Dehoff RM, et al. For the INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 2003;290:2805-2816.
14. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. For the VALIANT Investigators. Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the Valiant Trial. N Engl J Med 2003;349:1893-1906.
15. Blood Pressure Lowering treatment Trialists collaboration. Effects of different blood-pressure lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-1535.
16. Angeli F, Verdecchia P, Reboldi GP, et al. Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103 793 subjects. Am J Hypertens 2004;17:817-822.
17. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the captopril prevention project (CAPP) randomised trial. Lancet 1999;353:611-616.
18. The ALLHAT Officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
19. J Shortt. Obesity: a public health dilemma. AORN J 2004;80:1069-1078.
20. Writing Group of the PREMIER Collaborative Research Group. JAMA 2003;289:2083-2093.
21. Ishikawa-takata K, Ohta T, Tanaka H. How much exercise is required to reduce blood pressure in essential hypertension: a dose-response study. Am J Hypertens 2003;16:629-633.
22. Appel LJ, Moore TJ, Obarzanek E. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997; 336(16):1117-1124.
23. Sacks FM, Svetkey LP, Vollmer WM. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) DIET. N Engl J Med 2001;344:3-10.
24. Janssen I, Katzmarzyk PT, Ross R. Body mass index, waist circumference, and health risk: evidence in support of current National Institutes of Health guidelines. Arch Intern Med 2002;162:2074-2079.
25. Progress collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-1041.
26. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-767.
27. International society of hypertension Writing Group. International Society of hypertension (ISH): Statement on the Management of Blood Pressure in Acute Stroke. J Hypertens 2003;21:665-672.
28. Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA; First Collaborative Group. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002;33:1315-1320.
29. Schrader J, Luders S, Kulschewski A. The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003;34:1699-1703.
30. Adams HP, Chair J, Adams RJ, et al. Guidelines for the early management of patients with ischemic stroke. Stroke 2003;34:1056-1083.
31. Broderick JP, Adams HP, Barsan W, et al. Guidelines for the Management of spontaneous intracranial hemorrhage. Stroke 1999;30:905-915.
32. Anonymous. The National Institutes of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587.
33. Ahmed N, Nasman P, Wahlgren G. Effect of intravenous nimodipine on blood pressure and outcome after acute stroke. Stroke 2002;31:1250-1255.
34. Rosenbaum D, Zabramski J, Frey J, et al. Early treatment of ischemic stroke with a calcium antagonist. Stroke 1991;22:437-441.